- Home
- KVAC vs CHRS Comparison
KVAC vs CHRS Comparison
Compare KVAC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KVAC
- CHRS
- Stock Information
- Founded
- KVAC 2021
- CHRS 2010
- Country
- KVAC United States
- CHRS United States
- Employees
- KVAC N/A
- CHRS 235
- Industry
- KVAC
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KVAC
- CHRS Health Care
- Exchange
- KVAC Nasdaq
- CHRS Nasdaq
- Market Cap
- KVAC 212.1M
- CHRS 134.4M
- IPO Year
- KVAC 2023
- CHRS 2014
- Fundamental
- Price
- KVAC $11.10
- CHRS $1.21
- Analyst Decision
- KVAC
- CHRS Strong Buy
- Analyst Count
- KVAC 0
- CHRS 4
- Target Price
- KVAC N/A
- CHRS $5.38
- AVG Volume (30 Days)
- KVAC 4.9K
- CHRS 2.4M
- Earning Date
- KVAC 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- KVAC N/A
- CHRS N/A
- EPS Growth
- KVAC N/A
- CHRS N/A
- EPS
- KVAC 0.43
- CHRS N/A
- Revenue
- KVAC N/A
- CHRS $304,340,000.00
- Revenue This Year
- KVAC N/A
- CHRS $2.47
- Revenue Next Year
- KVAC N/A
- CHRS N/A
- P/E Ratio
- KVAC $25.73
- CHRS N/A
- Revenue Growth
- KVAC N/A
- CHRS 44.19
- 52 Week Low
- KVAC $10.37
- CHRS $0.66
- 52 Week High
- KVAC $11.10
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- KVAC 85.21
- CHRS 44.03
- Support Level
- KVAC $10.94
- CHRS $1.03
- Resistance Level
- KVAC $11.10
- CHRS $1.23
- Average True Range (ATR)
- KVAC 0.00
- CHRS 0.13
- MACD
- KVAC 0.00
- CHRS -0.02
- Stochastic Oscillator
- KVAC 90.00
- CHRS 38.89
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.